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productivity, and sustained virological response (SVR). METHODS: A PubMed 
search (all articles through April 16, 2009) using the following terms: Hepatitis C OR 
HCV; AND Quality of Life OR QoL OR Health Related Quality of Life OR hrQoL; 
AND Productivity OR Adherence OR Compliance OR General Health Status OR 
Treatment History. For inclusion, studies must have included primary data and inter-
feron-based therapies. Studies were excluded if non-English, or did not involve 
primary data from human subjects. RESULTS: Of 106 articles identiﬁed, 30 met 
review criteria. Nineteen studies compared pre-treatment hrQoL to healthy controls; 
14 (74%) found signiﬁcantly lower hrQoL among patients with Hepatitis C. Fourteen 
studied hrQoL during treatment, and signiﬁcant reductions were observed in all but 
one of the studies that tested for signiﬁcance. Two studies examined on-treatment 
productivity and hrQoL, and both reported signiﬁcant associations. Four examined 
associations between hrQoL and adherence, and two reported signiﬁcant positive 
associations; one did not achieve signiﬁcance and the other reported insufﬁcient data 
for analysis. Nine studies assessed post-treatment hrQoL differences based on treat-
ment response, and seven of these tested for signiﬁcance; of these, six (86%) found 
signiﬁcantly better hrQoL among patients achieving SVR than among non-SVR. 
CONCLUSIONS: In this analysis, most patients who achieved SVR experienced 
hrQoL improvements that approached healthy/well norms. This is noteworthy as 
patients with Hepatitis C exhibited poorer baseline hrQoL than healthy individuals 
and frequently reported diminished on-treatment hrQoL versus baseline. While data 
are robust for pre- and post-treatment hrQoL, many studies were not adequately 
powered to study on-treatment hrQoL, or its relationship to adherence. Future 
research is needed on the relationship between treatment discontinuation (i.e., viro-
logical non-response versus poor tolerability) and on-treatment hrQoL.
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OBJECTIVES: To assess patient satisfaction with proton pump inhibitors (PPIs) and 
H2-receptor antagonists (H2RAs), which are widely used to treat gastroesophageal 
reﬂux disease (GERD), among a community-based population in the US. METHODS: 
Patients are recruited for this ongoing disease registry from multiple sources including 
physician, pharmacy and online referrals to a medication monitoring service (www.
iGuard.org). A random sample of patients reporting using PPIs and H2RAs were 
invited to complete the Treatment Satisfaction Questionnaire for Medication Version 
1.4 (TSQM), a 14-item reliable and valid instrument to assess patients’ satisfaction 
with medication, providing scores on four scales—Effectiveness, Side Effects, Conven-
ience and Global Satisfaction. Analyses were conducted to evaluate differences in 
patient satisfaction across GERD medication class (PPIs vs. H2RAs) and individual 
medications within each class using analysis of covariance models. RESULTS: Data 
from a total of 1896 patients, 1629 on PPIs and 267 on H2RAs were analyzed for 
this study. Among PPIs, 498 patients were on esomeprazole, 199 on lansoprazole, 690 
on omeprazole, 160 on pantoprazole and 82 on rabeprazole. Among H2RAs, 24 
patients were on cimetidine, 63 on famotidine and 180 on ranitidine. After adjusting 
for patient age, gender, self-reported severity and number of concomitant medications, 
patients on PPIs had signiﬁcantly higher scores on Effectiveness (p < 0.0001), Con-
venience (p = 0.0007) and Global Satisfaction (p = 0.0003) as compared to H2RAs. 
After controlling for multiple comparisons, no signiﬁcant differences were observed 
in TSQM scale scores for individual H2RA medications, however some signiﬁcant 
differences were observed within PPIs. For example, patients on esomeprazole (p < 
0.0001), pantoprazole (p = 0.0391) and rabeprazole (p = 0.0021) had a signiﬁcantly 
higher score on Convenience compared to patients on omeprazole. CONCLUSIONS: 
This large observational study found signiﬁcant differences in treatment satisfaction 
with different GERD treatment classes and individual medications. This real-world 
feedback from patients can assist clinicians in making treatment decisions.
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OBJECTIVES: Acid-related diseases of the gastrointestinal system affect an estimated 
29% of Canadian adults. Two drug classes, proton pump inhibitors (PPIs) and hista-
mine–2 receptor antagonists (H2RAs) are commonly used to prevent and treat these 
conditions. PPIs have shown improved efﬁcacy over H2RAs, and are generally con-
sidered to be safe medications with few adverse effects. However, there have been 
increasing concerns regarding adverse effects associated with long-term and high-dose 
PPI use. METHODS: Claims level data from the National Prescription Drug Utiliza-
tion Information System (NPDUIS) Database were analyzed for seniors on public drug 
programs in 6 Canadian provinces between 2001–2002 and 2006–2007. This analysis 
compares PPI use to that of H2RAs and breaks down use by age and sex. The analysis 
also explores the inﬂuence PPI dosages and length of therapy may be having on the 
overall trend in PPI use. RESULTS: The age–sex standardized rate of PPI use among 
seniors on public drug programs increased from 13.1% in 2001–2002, to 21.1% in 
2007–2008. During the same time period, H2RA use fell from 12.7% to 8.8%. The 
average daily dose of PPIs used by seniors on public drug programs remained relatively 
stable, with roughly 80% of PPI claimants using an average daily dose within the 
standard dosage range each year. The rate of chronic PPI use increased, with 65.8% 
of seniors taking PPIs considered to be chronic users in 2007–2008. CONCLUSIONS: 
There was a signiﬁcant increase in the use of PPIs among seniors on public drug 
programs in Canada, which coincided with a decrease in H2RA use. Although the 
average daily dose of PPIs used by these seniors did not increase during the study 
period, a higher proportion of seniors were taking PPIs for longer periods of time.
PGI36
USING PROPENSITY SCORE MATCHING TO ESTIMATE DIFFERENCES 
IN HEALTH CARE UTILIZATION BETWEEN PEOPLE WITH AND 
WITHOUT ULCERATIVE COLITIS
Thanh NX, Ohinmaa A, Jacobs P
Institute of Health Economics, Edmonton, AB, Canada
OBJECTIVES: To estimate the average difference in health care utilization between 
people with and without ulcerative colitis (UC) in Canada. METHODS: Using the 
2007–2008 Canadian Community Health Survey data, we applied a single-difference 
propensity score matching approach to estimate the average differences in the number 
of inpatient days, the number of family physician/general practitioner (GP) consulta-
tions, and the number of specialist (Sp) consultations per person per year in 12-year-
or-older population with and without UC. Variables included in a stepwise logistic 
regression with the sampling weight to estimate the propensity scores for matching 
were socio-demographic characteristics, perceived health, other chronic conditions, 
and health related behaviours. We used a bootstrap method to estimate the 95% 
conﬁdence intervals of the differences. We also used a balance test to estimate the bias 
before and after matching. RESULTS: Using the sampling weight, the UC prevalence 
rate in Canada was estimated at 0.46%. The average number per person per year of 
inpatient days was 1.396 and 0.868, of GP consultations was 5.006 and 3.553, and 
of Sp consultations was 1.538 and 0.903, for people with and without UC, respec-
tively. The average differences between people with and without UC in inpatient days, 
GP consultations, and Sp consultations were 0.528 (95%CI: 0.013–1.042), 1.453 
(95%CI: 0.598–2.308), and 0.635 (95%CI: 0.345–0.925), respectively. The balance 
test showed that the mean of bias was dramatically reduced after matching (from 21.0 
to 1.7). CONCLUSIONS: People with UC used signiﬁcantly more health care 
resources than those without the disease. Results of this study can be used to provide 
background information from the UC patients for evaluations of UC treatments and 
interventions.
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OBJECTIVES: Despite the potential advantages of enteral route, parenteral proton 
pump inhibitors (PPIs) are routinely ordered in the Intensive Care Unit (ICU) for stress 
ulcer prophylaxis (SUP). Therefore, we studied patient characteristics associated with 
enteral vs. parenteral PPI use in critically ill patients needing acid-suppression for SUP. 
METHODS: A retrospective study of electronic medical record data of ≥ 19 year-old 
adult patients admitted to a Midwest Academic Medical Center’s ICU was undertaken. 
Patients that received a PPI from January 2007 through December 2008 were included. 
Patient data {age, gender, nonoperative/postoperative status, number of underlying 
illnesses, any oral medication use, oro-gastric tube, nothing by oral route (NPO), 
resource utilization variables (hospital days, ICU days) and PPI-use (enteral/
parenteral)} were extracted. Statistical differences between enteral and parenteral PPI 
patient groups by each of the patient factors and resource utilization variables was 
determined using Chi-square or ﬁsher’s exact test and Wilcoxon-rank-sum tests. The 
association of speciﬁc patient characteristics (any oral medication use, oro-gastric 
tube, NPO) with enteral versus parenteral PPI-use was tested in univariate logistic 
regression analyses. RESULTS: Of 148 patients, 50% received enteral PPIs and 50% 
received parenteral PPIs. The enteral and parental PPI groups did not differ by mean 
age (60.2 versus 57.1 years, P > 0.05), male/female gender (52.7%/47.3% versus 
62.2%/37.8%, p > 0.50), nonoperative/postoperative patient-status (58.7%/41.3% 
versus 51.8%/48.3%, p > 0.05) or mean number of underlying illnesses (5.3 versus 
5.5, P > 0.05). The enteral and parental PPI groups differed signiﬁcantly by median 
hospital days (7.0 versus 11.0, p = 0.0018), and median ICU days (2.0 versus 3.0 p 
= 0.0325). In logistic regression analyses, any oral medication use, oro-gastric tube 
and NPO were not associated with enteral versus parenteral PPI-use (P > 0.05). 
CONCLUSIONS: Decisions on the use of parenteral versus enteral PPI need to con-
sider individual patient characteristics. To promote informed formulary decision-
making and cost-effective quality of care more research is needed.
